Home
About
Our Team
Stories
Careers
Products
Science
Pipeline and Clinical Trials
Cortisol Modulation
Therapeutic Areas
Publications
Investigator Initiated Studies
Resources
Medical Information Request
Grants
Compassionate use
State Required Notice
Investors
Overview
Press Releases
Events
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Contact
Search
Menu
Menu
Home
About
Teams
Stories
Careers
Products
Science
Pipeline and Clinical Trials
Cortisol Modulation
Therapeutic Areas
Publications
Investigator Initiated Studies
Resources
Medical Information Request
Grants
Compassionate use
State Required Notice
Contact
Investors
Overview
Press Releases
Events
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Terms of Use
Site Map
Stories
and perspectives.
Featured
Stories
We are Corcept.
Video:
Founding Corcept
Article:
All Stories
Understanding Ovarian Cancer Recurrence: What Every Woman Needs to Know
Article:
HONORING HENRIETTA VILLAESCUSA, RN, FAAN
Article:
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
Press Release: June 5, 2025
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Press Release: June 2, 2025
HONORING DR. SARA JOSEPHINE BAKER
Article:
HONORING DR. MIN CHIU LI
Article:
Corcept to Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ASCO 2025
Press Release: April 23, 2025
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
Press Release: April 21, 2025
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Press Release: Mar 31, 2025
Page 1 of 3
1
2
3
Scroll to top
Scroll to top
Scroll to top
